
Peter John Scammells

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8584520/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Structural Features of Iperoxo–BQCA Muscarinic Acetylcholine Receptor Hybrid Ligands Determining Subtype Selectivity and Efficacy. ACS Chemical Neuroscience, 2022, 13, 97-111.	3.5	4
2	Biocompatible Cationic Lipoamino Acids as Counterions for Oral Administration of API-Ionic Liquids. Pharmaceutical Research, 2022, 39, 2405-2419.	3.5	3
3	A Structureâ^'Activity Relationship Study of Novel Hydroxamic Acid Inhibitors around the S1 Subsite of Human Aminopeptidase N. ChemMedChem, 2021, 16, 234-249.	3.2	0
4	Development of Novel 4â€Arylpyridinâ€2â€one and 6â€Arylpyrimidinâ€4â€one Positive Allosteric Modulators of t M 1 Muscarinic Acetylcholine Receptor. ChemMedChem, 2021, 16, 216-233.	he 3.2	4
5	Development and Application of Subtype-Selective Fluorescent Antagonists for the Study of the Human Adenosine A ₁ Receptor in Living Cells. Journal of Medicinal Chemistry, 2021, 64, 6670-6695.	6.4	6
6	Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formulations. International Journal of Pharmaceutics, 2021, 597, 120292.	5.2	8
7	Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide. Pharmaceutical Research, 2021, 38, 1125-1137.	3.5	6
8	Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor. Molecules, 2021, 26, 3799.	3.8	2
9	1,3â€Benzodioxoleâ€Modified Noscapine Analogues: Synthesis, Antiproliferative Activity, and Tubulinâ€Bound Structure. ChemMedChem, 2021, 16, 2882-2894.	3.2	6
10	Discovery and development of 2-aminobenzimidazoles as potent antimalarials. European Journal of Medicinal Chemistry, 2021, 221, 113518.	5.5	11
11	The effect of two selective A ₁ â€receptor agonists and the bitopic ligand <scp>VCP746</scp> on heart rate and regional vascular conductance in conscious rats. British Journal of Pharmacology, 2020, 177, 346-359.	5.4	5
12	Subtype-Selective Fluorescent Ligands as Pharmacological Research Tools for the Human Adenosine A _{2A} Receptor. Journal of Medicinal Chemistry, 2020, 63, 2656-2672.	6.4	25
13	Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure. Pharmaceutics, 2020, 12, 17.	4.5	25
14	Rapid Elaboration of Fragments into Leads by X-ray Crystallographic Screening of Parallel Chemical Libraries (REFiL _X). Journal of Medicinal Chemistry, 2020, 63, 6863-6875.	6.4	16
15	API ionic liquids: probing the effect of counterion structure on physical form and lipid solubility. RSC Advances, 2020, 10, 12788-12799.	3.6	12
16	Driving antimalarial design through understanding of target mechanism. Biochemical Society Transactions, 2020, 48, 2067-2078.	3.4	12
17	Subtle Modifications to the Indole-2-carboxamide Motif of the Negative Allosteric Modulator <i>N</i> -((<i>trans</i>)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1 <i>H</i>)-yl)ethyl)cyclohexyl)-1 <i>H</i> -indole-2 (SB269652) Yield Dramatic Changes in Pharmacological Activity at the Dopamine D ₂ Receptor, Journal of Medicinal Chemistry, 2019, 62, 371-377,	-carboxarr 6.4	nide 17
18	Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs. Nature	12.8	47

Communications, 2019, 10, 3289.

#	Article	IF	CITATIONS
19	Molecular Determinants of the Intrinsic Efficacy of the Antipsychotic Aripiprazole. ACS Chemical Biology, 2019, 14, 1780-1792.	3.4	19
20	Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions. Journal of Medicinal Chemistry, 2019, 62, 7185-7209.	6.4	17
21	A Novel Class ofNâ€Sulfonyl andNâ€Sulfamoyl Noscapine Derivatives that Promote Mitotic Arrest in Cancer Cells. ChemMedChem, 2019, 14, 1968-1981.	3.2	7
22	Structure–Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D ₂ Receptor. Journal of Medicinal Chemistry, 2019, 62, 9488-9520.	6.4	12
23	Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms. Advanced Drug Delivery Reviews, 2019, 142, 75-90.	13.7	39
24	Subtle modifications to a thieno[2,3-d]pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D2 receptor. European Journal of Medicinal Chemistry, 2019, 168, 474-490.	5.5	6
25	6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M ₁ mAChR: The Determinants of Allosteric Activity. ACS Chemical Neuroscience, 2019, 10, 1099-1114.	3.5	7
26	Identification of the Binding Site of Apical Membrane Antigenâ€1 (AMA1) Inhibitors Using a Paramagnetic Probe. ChemMedChem, 2019, 14, 603-612.	3.2	9
27	Probe dependence of allosteric enhancers on the binding affinity of adenosine A 1 â€receptor agonists at rat and human A 1 â€receptors measured using N ano BRET. British Journal of Pharmacology, 2019, 176, 864-878.	5.4	17
28	Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of <i>Plasmodium</i> M1 and M17 Aminopeptidases. Journal of Medicinal Chemistry, 2019, 62, 622-640.	6.4	30
29	Overcoming P-Glycoprotein–Mediated Drug Resistance with Noscapine Derivatives. Drug Metabolism and Disposition, 2019, 47, 164-172.	3.3	18
30	A Thieno[2,3- <i>d</i>]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D ₂ Receptor. Journal of Medicinal Chemistry, 2019, 62, 174-206.	6.4	20
31	A Structure–Activity Relationship Study of Bitopic <i>N</i> ⁶ -Substituted Adenosine Derivatives as Biased Adenosine A ₁ Receptor Agonists. Journal of Medicinal Chemistry, 2018, 61, 2087-2103.	6.4	29
32	The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions. Scientific Reports, 2018, 8, 1208.	3.3	16
33	The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D 2 receptor. Biochemical Pharmacology, 2018, 148, 315-328.	4.4	26
34	Fluorescently Labeled Morphine Derivatives for Bioimaging Studies. Journal of Medicinal Chemistry, 2018, 61, 1316-1329.	6.4	18
35	Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M ₁ Muscarinic Acetylcholine Receptors. Molecular Pharmacology, 2018, 94, 770-783.	2.3	10
36	Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M ₁ Muscarinic Acetylcholine Receptor with Weak Agonist Activity and Diverse Modulatory Profiles. Journal of Medicinal Chemistry, 2018, 61, 2875-2894.	6.4	14

#	Article	IF	CITATIONS
37	Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations. Journal of Pharmaceutical Sciences, 2018, 107, 203-216.	3.3	35
38	Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations. Molecular Pharmaceutics, 2018, 15, 5678-5696.	4.6	34
39	Synthesis and Pharmacological Evaluation of Noscapine-Inspired 5-Substituted Tetrahydroisoquinolines as Cytotoxic Agents. Journal of Medicinal Chemistry, 2018, 61, 8444-8456.	6.4	20
40	Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor. Biochemical Pharmacology, 2018, 154, 243-254.	4.4	19
41	Liquid Assisted Grinding for the N-Demethylation of Alkaloids. ACS Sustainable Chemistry and Engineering, 2018, 6, 10052-10057.	6.7	17
42	Adenosine G Proteinâ€Coupled Receptor Biased Agonism to Treat Ischemic Heart Disease. FASEB Journal, 2018, 32, 555.19.	0.5	0
43	Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity. Cell, 2017, 168, 867-877.e13.	28.9	237
44	Utility of iron nanoparticles and a solution-phase iron species for the N-demethylation of alkaloids. Green Chemistry, 2017, 19, 2587-2594.	9.0	13
45	Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies. Molecular Pharmaceutics, 2017, 14, 3669-3683.	4.6	49
46	Antimalarial drug discovery targeting apical membrane antigen 1. MedChemComm, 2017, 8, 13-20.	3.4	8
47	Solution NMR characterization of apical membrane antigen 1 and small molecule interactions as a basis for designing new antimalarials. Journal of Molecular Recognition, 2016, 29, 281-291.	2.1	8
48	Role of the Second Extracellular Loop of the Adenosine A ₁ Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity. Molecular Pharmacology, 2016, 90, 715-725.	2.3	56
49	Novel Irreversible Agonists Acting at the A ₁ Adenosine Receptor. Journal of Medicinal Chemistry, 2016, 59, 11182-11194.	6.4	20
50	Structure and substrate fingerprint of aminopeptidase P from <i>Plasmodium falciparum</i> . Biochemical Journal, 2016, 473, 3189-3204.	3.7	11
51	<scp>VCP</scp> 746, a novel A ₁ adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 976-982.	1.9	20
52	The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling. Biochemical Pharmacology, 2016, 117, 46-56.	4.4	30
53	Multivalent approaches and beyond: novel tools for the investigation of dopamine D ₂ receptor pharmacology. Future Medicinal Chemistry, 2016, 8, 1349-1372.	2.3	8
54	Guidelines for the Synthesis of Smallâ€Molecule Irreversible Probes Targeting Gâ€Protein oupled Receptors. ChemMedChem, 2016, 11, 1488-1498.	3.2	14

#	Article	IF	CITATIONS
55	The role of kinetic context in apparent biased agonism at GPCRs. Nature Communications, 2016, 7, 10842.	12.8	270
56	Positive Allosteric Modulation of the Muscarinic M ₁ Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 354-365.	2.5	21
57	Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions. European Journal of Medicinal Chemistry, 2016, 110, 43-64.	5.5	46
58	Novel Fused Arylpyrimidinone Based Allosteric Modulators of the M ₁ Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2016, 7, 647-661.	3.5	14
59	4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M ₁ Muscarinic Acetylcholine Receptor. Journal of Medicinal Chemistry, 2016, 59, 388-409.	6.4	35
60	Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18. PLoS ONE, 2015, 10, e0115859.	2.5	34
61	Design, Synthesis, and Biological Evaluation of Tetraâ€Substituted Thiophenes as Inhibitors of p38α MAPK. ChemistryOpen, 2015, 4, 56-64.	1.9	12
62	Synthesis, Biological Evaluation, and Utility of Fluorescent Ligands Targeting the μ-Opioid Receptor. Journal of Medicinal Chemistry, 2015, 58, 9754-9767.	6.4	23
63	Promiscuous 2-Aminothiazoles (PrATs): A Frequent Hitting Scaffold. Journal of Medicinal Chemistry, 2015, 58, 1205-1214.	6.4	75
64	Structure–Activity Study of <i>N</i> -((<i>trans</i>)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1 <i>H</i>)-yl)ethyl)cyclohexyl)-1 <i>H</i> -indole-2 (SB269652), a Bitopic Ligand That Acts as a Negative Allosteric Modulator of the Dopamine D ₂ Receptor. Journal of Medicinal Chemistry, 2015, 58, 5287-5307.	2-carboxar 6.4	nide 40
65	Transformation of Poorly Water-Soluble Drugs into Lipophilic Ionic Liquids Enhances Oral Drug Exposure from Lipid Based Formulations. Molecular Pharmaceutics, 2015, 12, 1980-1991.	4.6	121
66	Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents. Journal of Medicinal Chemistry, 2015, 58, 5699-5727.	6.4	74
67	Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D ₂ Receptor Through Fragmentation of a Bitopic Ligand. Journal of Medicinal Chemistry, 2015, 58, 6819-6843.	6.4	47
68	Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4614-4619.	7.1	92
69	NMR case study of ropinirole: concentration-dependent effects of nonexchangeable proton resonances. Magnetic Resonance in Chemistry, 2014, 52, 715-718.	1.9	3
70	Mechanistic Insights into Allosteric Structure-Function Relationships at the M1 Muscarinic Acetylcholine Receptor. Journal of Biological Chemistry, 2014, 289, 33701-33711.	3.4	49
71	Molecular Mechanisms of Bitopic Ligand Engagement with the M1 Muscarinic Acetylcholine Receptor. Journal of Biological Chemistry, 2014, 289, 23817-23837.	3.4	55
72	The Synthesis and Biological Evaluation of Multifunctionalised Derivatives of Noscapine as Cytotoxic Agents. ChemMedChem, 2014, 9, 399-410.	3.2	28

#	Article	IF	CITATIONS
73	Structure and Dynamics of Apical Membrane Antigen 1 from <i>Plasmodium falciparum</i> FVO. Biochemistry, 2014, 53, 7310-7320.	2.5	23
74	A critical evaluation of pyrrolo[2,3-d]pyrimidine-4-amines as Plasmodium falciparum apical membrane antigen 1 (AMA1) inhibitors. MedChemComm, 2014, 5, 1500-1506.	3.4	8
75	Design, synthesis and evaluation of N6-substituted 2-aminoadenosine-5′-N-methylcarboxamides as A3 adenosine receptor agonists. MedChemComm, 2014, 5, 192-196.	3.4	6
76	Synthesis and Pharmacological Evaluation of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) Designed to Bind Irreversibly to an Allosteric Site of the M1Muscarinic Acetylcholine Receptor. Journal of Medicinal Chemistry, 2014, 57, 5405-5418.	6.4	27
77	A new mechanism of allostery in a G protein–coupled receptor dimer. Nature Chemical Biology, 2014, 10, 745-752.	8.0	108
78	Ligand-Induced Conformational Change of <i>Plasmodium falciparum</i> AMA1 Detected Using ¹⁹ F NMR. Journal of Medicinal Chemistry, 2014, 57, 6419-6427.	6.4	33
79	Investigation of novel ropinirole analogues: synthesis, pharmacological evaluation and computational analysis of dopamine D2 receptor functionalized congeners and homobivalent ligands. MedChemComm, 2014, 5, 891-898.	3.4	23
80	Development of a Photoactivatable Allosteric Ligand for the M ₁ Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2014, 5, 902-907.	3.5	9
81	Two-Pronged Attack: Dual Inhibition of <i>Plasmodium falciparum</i> M1 and M17 Metalloaminopeptidases by a Novel Series of Hydroxamic Acid-Based Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 9168-9183.	6.4	52
82	lonic liquids provide unique opportunities for oral drug delivery: structure optimization and in vivo evidence of utility. Chemical Communications, 2014, 50, 1688-1690.	4.1	118
83	Synthesis of Thienoâ€Fused Heterocycles through Reiterative Iodocyclization. Advanced Synthesis and Catalysis, 2014, 356, 1974-1978.	4.3	36
84	Synthesis, functional and binding profile of (R)-apomorphine based homobivalent ligands targeting the dopamine D2 receptor. MedChemComm, 2013, 4, 1290.	3.4	9
85	Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A2A antagonist, ZM 241385. Structural Chemistry, 2013, 24, 1241-1251.	2.0	11
86	Reverse Engineering of the Selective Agonist TBPB Unveils Both Orthosteric and Allosteric Modes of Action at the M1 Muscarinic Acetylcholine Receptor. Molecular Pharmacology, 2013, 84, 425-437.	2.3	31
87	A Multi-Step Continuous Flow Process for the N-Demethylation of Alkaloids. Australian Journal of Chemistry, 2013, 66, 178.	0.9	15
88	Synthesis and Structure–Activity Relationships of Phosphonic Arginine Mimetics as Inhibitors of the M1 and M17 Aminopeptidases from <i>Plasmodium falciparum</i> . Journal of Medicinal Chemistry, 2013, 56, 5213-5217.	6.4	53
89	Synthesis and Pharmacological Profiling of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) as Allosteric Modulators of the M ₁ Muscarinic Receptor. Journal of Medicinal Chemistry, 2013, 56, 5151-5172.	6.4	53
90	Development of Inhibitors of Plasmodium falciparum Apical Membrane Antigen 1 Based on Fragment Screening. Australian Journal of Chemistry, 2013, 66, 1530.	0.9	20

#	Article	IF	CITATIONS
91	Polonovski-Type N-Demethylation of N-Methyl Alkaloids Using Substituted Ferrocene Redox Catalysts. Synthesis, 2012, 44, 2587-2594.	2.3	10
92	Synthesis and Biological Evaluation of <i>N</i> ‣ubstituted Noscapine Analogues. ChemMedChem, 2012, 7, 2122-2133.	3.2	46
93	Synthesis and Characterization of Novel 2-Amino-3-benzoylthiophene Derivatives as Biased Allosteric Agonists and Modulators of the Adenosine A ₁ Receptor. Journal of Medicinal Chemistry, 2012, 55, 2367-2375.	6.4	53
94	Improved synthesis of 14-hydroxy opioid pharmaceuticals and intermediates. RSC Advances, 2012, 2, 11318.	3.6	13
95	A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation. Journal of Biological Chemistry, 2012, 287, 650-659.	3.4	98
96	Synthesis and Biological Evaluation of Adenosines with Heterobicyclic and Polycyclic <i>N</i> ⁶ ‣ubstituents as Adenosine A ₁ Receptor Agonists. ChemMedChem, 2012, 7, 1191-1201.	3.2	5
97	Further investigations into the N-demethylation of oripavine using iron and stainless steel. Organic and Biomolecular Chemistry, 2011, 9, 1008-1011.	2.8	19
98	Efficient Iron-Catalyzed N-Demethylation of Tertiary Amine-N-oxides under Oxidative Conditions. Australian Journal of Chemistry, 2011, 64, 1515.	0.9	15
99	Synthesis and Utility of 2â€Haloâ€ <i>O</i> ⁶ â€(benzotriazolâ€1â€yl)â€Functionalized Purine Nucleosides. European Journal of Organic Chemistry, 2011, 2011, 1092-1098.	2.4	17
100	Grignard Reactions in Pyridinium and Phosphonium Ionic Liquids. European Journal of Organic Chemistry, 2011, 2011, 942-950.	2.4	31
101	Delineating the Mode of Action of Adenosine A ₁ Receptor Allosteric Modulators. Molecular Pharmacology, 2010, 78, 444-455.	2.3	39
102	Effects of Conformational Restriction of 2-Amino-3-benzoylthiophenes on A ₁ Adenosine Receptor Modulation. Journal of Medicinal Chemistry, 2010, 53, 6550-6559.	6.4	31
103	Two-Step Iron(0)-Mediated N-Demethylation of <i>N</i> -Methyl Alkaloids. Journal of Organic Chemistry, 2010, 75, 4806-4811.	3.2	50
104	Sonogashira coupling reactions in biodegradable ionic liquids derived from nicotinic acid. Green Chemistry, 2010, 12, 650.	9.0	58
105	Further studies on the biodegradation of ionic liquids. Green Chemistry, 2010, 12, 1783.	9.0	61
106	Determination of Adenosine A ₁ Receptor Agonist and Antagonist Pharmacology Using <i>Saccharomyces cerevisiae</i> : Implications for Ligand Screening and Functional Selectivity. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 277-286.	2.5	46
107	3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists. Bioorganic and Medicinal Chemistry, 2009, 17, 7353-7361.	3.0	41
108	RAFT-Mediated Polymerization of Styrene in Readily Biodegradable Ionic Liquids. Macromolecules, 2009, 42, 1604-1609.	4.8	28

#	Article	IF	CITATIONS
109	Further investigation of the biodegradability of imidazolium ionic liquids. Green Chemistry, 2009, 11, 821.	9.0	112
110	Biodegradable pyridinium ionic liquids: design, synthesis and evaluation. Green Chemistry, 2009, 11, 83-90.	9.0	156
111	Phosphonium ionic liquids: design, synthesis and evaluation of biodegradability. Green Chemistry, 2009, 11, 1595.	9.0	137
112	Allosteric Modulators of the Adenosine A ₁ Receptor: Synthesis and Pharmacological Evaluation of 4-Substituted 2-Amino-3-benzoylthiophenes. Journal of Medicinal Chemistry, 2009, 52, 4543-4547.	6.4	124
113	N6-substituted C5′-modified adenosines as A1 adenosine receptor agonists. Bioorganic and Medicinal Chemistry, 2008, 16, 1861-1873.	3.0	20
114	The design and synthesis of biodegradable pyridinium ionic liquids. Green Chemistry, 2008, 10, 436.	9.0	90
115	A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity. Journal of Biological Chemistry, 2008, 283, 29312-29321.	3.4	165
116	New Methodology for the N-Demethylation of Opiate Alkaloids. Journal of Organic Chemistry, 2007, 72, 9881-9885.	3.2	67
117	Effect of a novel partial adenosine A1 receptor agonist VCP102 in reducing ischemic damage in the mouse heart. Drug Development Research, 2007, 68, 529-537.	2.9	5
118	Biodegradable ionic liquids : Part III. The first readily biodegradable ionic liquids. Green Chemistry, 2006, 8, 156.	9.0	282
119	Further investigation of the N-demethylation of tertiary amine alkaloids using the non-classical Polonovski reaction. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2868-2871.	2.2	33
120	Biodegradable ionic liquids : Part II. Effect of the anion and toxicology. Green Chemistry, 2005, 7, 9.	9.0	496
121	Quantification of chloride ion impurities in ionic liquids using ICP-MS analysis. Green Chemistry, 2004, 6, 341.	9.0	34
122	Biodegradable ionic liquids: Part I. Concept, preliminary targets and evaluation. Green Chemistry, 2004, 6, 166.	9.0	452
123	Efficient N-Demethylation of Opiate Alkaloids Using a Modified Nonclassical Polonovski Reaction. Journal of Organic Chemistry, 2003, 68, 9847-9850.	3.2	82
124	New irreversible adenosine A1 antagonists based on FSCPX. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3179-3182.	2.2	8
125	New 2,N6-Disubstituted adenosines: potent and selective A1 adenosine receptor agonists. Bioorganic and Medicinal Chemistry, 2002, 10, 1115-1122.	3.0	26
126	Fluorosulfonyl-Substituted Xanthines as Selective Irreversible Antagonists for the A1-Adenosine Receptor. Journal of Medicinal Chemistry, 2000, 43, 4973-4980.	6.4	32

#	Article	IF	CITATIONS
127	Substituted 1,3-Dipropylxanthines as Irreversible Antagonists of A1 Adenosine Receptors. Journal of Medicinal Chemistry, 1994, 37, 2704-2712.	6.4	41
128	Examining the Role of the Linker in Bitopic <i>N</i> ⁶ -Substituted Adenosine Derivatives Acting as Biased Adenosine A ₁ Receptor Agonists. Journal of Medicinal Chemistry, 0, , .	6.4	1